Compare
Black Hawk Acquisition Corp vs Champions Oncology, Inc. vs CEL SCI Corp vs Atara Biotherapeutics, Inc.
| Latest fiscal year | Black Hawk Acquisition Corp BKHA | Champions Oncology, Inc. CSBR | CEL SCI Corp CVM | Atara Biotherapeutics, Inc. ATRA |
|---|---|---|---|---|
| Year ended | 2025-11-30 | 2026-04-30 | 2025-09-30 | 2025-12-31 |
| Revenue | n/a | $59.42M | n/a | $120.77M |
| Revenue growth (YoY) | n/a | +4.4% | n/a | -6.3% |
| Gross margin | n/a | 48.0% (computed) | n/a | n/a |
| Operating margin | n/a | -1.9% | n/a | 29.7% |
| Net margin | n/a | -2.0% | n/a | 27.1% |
| Net income | $1.33M | -$1.18M | -$25.41M | $32.69M |
| EPS (Diluted) | n/a | -$0.08 | -$6.27 | $2.57 |
| Operating cash flow | -$650.3K | -$4.47M | -$17.12M | -$50.94M |
| Free cash flow | n/a | -$5.04M | -$17.16M | -$50.94M |
| Cash & equivalents | $0 | n/a | n/a | $8.48M |
| Total assets | $23.88M | $26.99M | $28.16M | $20.23M |
| Total liabilities | $3.90M | $22.92M | $12.20M | $58.74M |
| Shareholders' equity | -$3.85M | $3.94M | $15.96M | -$38.50M |
| Return on year-end equity | n/a | -29.8% | -159.2% | n/a |
| Shares outstanding | n/a | 13.89M | 8.02M | 7.32M |
Revenue, most recent five fiscal years
| Fiscal year | Black Hawk Acquisition Corp | Champions Oncology, Inc. | CEL SCI Corp | Atara Biotherapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $59.42M Ended 2026-04-30 | $264.0K Ended 2014-09-30 | $120.77M Ended 2025-12-31 |
| 1 year earlier | n/a | $56.94M Ended 2025-04-30 | $159.6K Ended 2013-09-30 | $128.94M Ended 2024-12-31 |
| 2 years earlier | n/a | $50.16M Ended 2024-04-30 | $254.6K Ended 2012-09-30 | $8.57M Ended 2023-12-31 |
| 3 years earlier | n/a | $53.87M Ended 2023-04-30 | $956.2K Ended 2011-09-30 | $63.57M Ended 2022-12-31 |
| 4 years earlier | n/a | $49.11M Ended 2022-04-30 | n/a | n/a |